Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Rituximab, bortezomib, modified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) induction chemoimmunotherapy and maintenance rituximab (MR) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405. Patients with previously untreated mantl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chang, Julie E., Li, Hailun, Smith, Mitchell R., Gascoyne, Randy D., Paietta, Elisabeth M., Yang, David T., Advani, Ranjana H., Horning, Sandra J., Kahl, Brad S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3954048/
https://ncbi.nlm.nih.gov/pubmed/24458437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-08-523845
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados